Overbought Stocks
ORKA appears in our Overbought Stocks screen, meaning it has experienced strong recent gains and may be trading at extended levels that could lead to short-term consolidation or pullback.
ORUKA THERAPEUTICS INC (ORKA) Stock Price & Overview
NASDAQ:ORKA • US6876041087
Current stock price
53.31 USD
+2.88 (+5.71%)
At close:
53 USD
-0.31 (-0.58%)
After Hours:
The current stock price of ORKA is 53.31 USD. Today ORKA is up by 5.71%. In the past month the price increased by 60.72%. In the past year, price increased by 580.84%.
ORKA Key Statistics
52-Week Range5.485 - 53.56
Current ORKA stock price positioned within its 52-week range.
1-Month Range31.32 - 53.56
Current ORKA stock price positioned within its 1-month range.
- Market Cap
- 2.641B
- P/E
- N/A
- Fwd P/E
- N/A
- EPS (TTM)
- -1.86
- Dividend Yield
- N/A
ORKA Stock Performance
Today
+5.71%
1 Week
+17.27%
1 Month
+60.72%
3 Months
+88.57%
Longer-term
6 Months +169.38%
1 Year +580.84%
2 Years N/A
3 Years N/A
5 Years N/A
10 Years N/A
ORKA Stock Chart
ORKA Stock Screens
ORKA currently appears in the following ChartMill screener lists.
RSI Overbought Stocks
ORKA is RSI overbought, meaning strong buying pressure may lead to a short-term consolidation or pullback.
ORKA Technical Analysis
ChartMill assigns a technical rating of 10 / 10 to ORKA. When comparing the yearly performance of all stocks, ORKA is one of the better performing stocks in the market, outperforming 99.35% of all stocks.
Chartmill TA Rating
Chartmill Setup Rating
ORKA Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to ORKA. No worries on liquidiy or solvency for ORKA as it has an excellent financial health rating, but there are worries on the profitability.
Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend
ORKA Earnings
Next Earnings DateMay 12, 2026
Last Earnings DateMar 12, 2026
PeriodQ4 / 2025
EPS Reported-$0.45
Revenue Reported
EPS Surprise 29.68%
Revenue Surprise %
ORKA Forecast & Estimates
20 analysts have analysed ORKA and the average price target is 62.46 USD. This implies a price increase of 17.16% is expected in the next year compared to the current price of 53.31.
Analysts
Analysts88
Price Target62.46 (17.16%)
EPS Next Y-39.33%
Revenue Next YearN/A
ORKA Groups
Sector & Classification
ORKA Financial Highlights
Over the last trailing twelve months ORKA reported a non-GAAP Earnings per Share(EPS) of -1.86. The EPS increased by 65.58% compared to the year before.
Income Statements
Revenue(TTM)N/A
Net Income(TTM)-105.43M
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -21.58% | ||
| ROE | -22.34% | ||
| Debt/Equity | 0 |
Chartmill High Growth Momentum
EPS Q2Q%8.16%
Sales Q2Q%N/A
EPS 1Y (TTM)65.58%
Revenue 1Y (TTM)N/A
ORKA Ownership
Ownership
Inst Owners108.04%
Shares49.54M
Float46.34M
Ins Owners3.56%
Short Float %7.86%
Short Ratio6.76
ORKA Competitors/Peers
The largest stocks on the US markets in the "Biotechnology" sub-industry
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 14.07 | 369.265B | ||
| AMGN | AMGEN INC | 15.24 | 187.564B | ||
| GILD | GILEAD SCIENCES INC | 15.81 | 173.439B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 22.63 | 111.445B | ||
| REGN | REGENERON PHARMACEUTICALS | 16.3 | 80.543B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 42.73 | 42.286B | ||
| INSM | INSMED INC | N/A | 35.012B | ||
| NTRA | NATERA INC | N/A | 29.477B | ||
| BIIB | BIOGEN INC | 11.03 | 26.026B | ||
| UTHR | UNITED THERAPEUTICS CORP | 18.91 | 24.756B | ||
| RVMD | REVOLUTION MEDICINES INC | N/A | 19.643B | ||
| MRNA | MODERNA INC | N/A | 19.431B | ||
| INCY | INCYTE CORP | 12.53 | 19.091B |
Related stock screener links
View all stocks in the Biotechnology Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About ORKA
Company Profile
Oruka Therapeutics, Inc. is a biotechnology company, which focuses on developing novel monoclonal antibody therapeutics for PsO and other I&I indications. The company is headquartered in Menlo Park, California and currently employs 68 full-time employees. The company went IPO on 2000-07-21. The firm is focused on developing novel monoclonal antibody therapeutics for psoriasis (PsO) and other inflammatory and immunology (I&I) indications. Its lead program, ORKA-001, is designed to target the p19 subunit of interleukin-23 (IL-23p19) for the treatment of PsO. Its co-lead program, ORKA-002, is designed to target interleukin-17A and interleukin-17F (IL-17A/F) for the treatment of PsO, psoriatic arthritis (PsA), and other conditions. ORKA-001 is an extended half-life monoclonal antibody (mAb) designed to target IL-23p19. IL-23 is a pro-inflammatory cytokine that plays a critical role in the proliferation and development of T helper 17 (Th17) cells, which are the primary drivers of several autoimmune and inflammatory disorders, including PsO. IL-23 is composed of two subunits: a p40 subunit and a p19 subunit. ORKA-002 is an extended half-life mAb designed to target IL-17A and IL-17F (IL-17A/F).
Company Info
IPO: 2000-07-21
ORUKA THERAPEUTICS INC
855 Oak Grove Ave., Suite 100
Menlo Park CALIFORNIA US
Employees: 68
Phone: 13026587581
ORUKA THERAPEUTICS INC / ORKA FAQ
Can you describe the business of ORUKA THERAPEUTICS INC?
Oruka Therapeutics, Inc. is a biotechnology company, which focuses on developing novel monoclonal antibody therapeutics for PsO and other I&I indications. The company is headquartered in Menlo Park, California and currently employs 68 full-time employees. The company went IPO on 2000-07-21. The firm is focused on developing novel monoclonal antibody therapeutics for psoriasis (PsO) and other inflammatory and immunology (I&I) indications. Its lead program, ORKA-001, is designed to target the p19 subunit of interleukin-23 (IL-23p19) for the treatment of PsO. Its co-lead program, ORKA-002, is designed to target interleukin-17A and interleukin-17F (IL-17A/F) for the treatment of PsO, psoriatic arthritis (PsA), and other conditions. ORKA-001 is an extended half-life monoclonal antibody (mAb) designed to target IL-23p19. IL-23 is a pro-inflammatory cytokine that plays a critical role in the proliferation and development of T helper 17 (Th17) cells, which are the primary drivers of several autoimmune and inflammatory disorders, including PsO. IL-23 is composed of two subunits: a p40 subunit and a p19 subunit. ORKA-002 is an extended half-life mAb designed to target IL-17A and IL-17F (IL-17A/F).
Can you provide the latest stock price for ORUKA THERAPEUTICS INC?
The current stock price of ORKA is 53.31 USD. The price increased by 5.71% in the last trading session.
Does ORUKA THERAPEUTICS INC pay dividends?
ORKA does not pay a dividend.
What is the ChartMill rating of ORUKA THERAPEUTICS INC stock?
ORKA has a ChartMill Technical rating of 10 out of 10 and a ChartMill Fundamental rating of 3 out of 10.
Can you provide the number of employees for ORUKA THERAPEUTICS INC?
ORUKA THERAPEUTICS INC (ORKA) currently has 68 employees.
Can you provide the market cap for ORUKA THERAPEUTICS INC?
ORUKA THERAPEUTICS INC (ORKA) has a market capitalization of 2.64B USD. This makes ORKA a Mid Cap stock.
What is the ownership structure of ORUKA THERAPEUTICS INC (ORKA)?
You can find the ownership structure of ORUKA THERAPEUTICS INC (ORKA) on the Ownership tab.